Novel nucleoside analogs
CA 2089377 C · Owner: Isis Pharmaceuticals Inc. · Inventors: Sanghvi, Yogesh Shantilal; Cook, Phillip Dan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel oligonucleotide analogs are provided having improved cellullar uptake improved resistance to nucleases, and good hybridization to target RNA. Such analogs are provided having substantially non-chiral, non-ionic linking functionalities between the sugars and sugar analogs thereof. In accordance with preferred embodiments, the 4' position of a sugar or sugar analog at one nucleoside is linked to the 3' position of a second sugar or sugar analog of a second nucleoside by a linking function that comprises a two- or three- carbon backbone chain. In accordance with preferred embodiments, the linking functions comprise the formula O-R1-O where R1 comprises a two or three carbon …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 12, 1991 and granted June 20, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 12, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 12, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.